Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.164 SNIP: 0.041 CiteScore™: 0.18

ISSN Imprimir: 2151-8017
ISSN En Línea: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.v1.i1-2.40
pages 51-64

YY1 as a Therapeutic Target in Cancer

Khimara Naidoo
Academic Foundation Programme, St Thomas’ Hospital, Guys and St Thomas’ National Health Service Foundation Trust, London, United Kingdom
Richard J. Byers
School of Cancer Imaging Sciences, Faculty of Medical and Human Sciences, The University of Manchester; and Department of Histopathology, Manchester Royal Infirmary, Manchester, United Kingdom


The transcription factor YY1 controls many divergent cellular processes, including cell proliferation and apoptosis. Because these processes are key to cancer development, the expression of YY1 is altered in many cancers, including lymphoma, prostatic cancer, osteosarcoma, ovarian cancer and leukemia. Its expression has been associated with development of the malignant phenotype, with tumor progression including metastasis, and with survival. Consequently, there has been recent interest in the possible role of YY1 as a therapeutic target. This article reviews the role of YY1 in the control of cell cycle and apoptosis, and provides a detailed discussion of its role in a range of human tumors. YY1 acts to inhibit Fas-mediated apoptosis, although this inhibition is reduced by treatment with rituximab. Similarly, YY1 acts to downregulate TRAIL-induced apoptosis, although this effect can be reversed by treatment with nitric oxide donors, suggesting a possible role for the use of nitric oxide and TRAIL agonists in chemoresistant tumors such as melanoma. Although research is in the early stages, the central position of YY1 in the control of key cellular processes and its association with several cancers renders particularly exciting therapeutic interventions.

Articles with similar content:

Roles of Smad3 in TGF-β Signaling During Carcinogenesis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.17, 2007, issue 4
Caroline Millet, Ying E. Zhang
Antitumoral Activity of Sorafenib in Hepatocellular Carcinoma: Effects on Cell Survival and Death Pathways, Cell Metabolism Reprogramming, and Nitrosative and Oxidative Stress
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 5-6
Francisco J. Padillo, Jordi Muntané, Maria A. Rodriguez-Hernandez, Elena Navarro-Villaran, Raul Gonzalez, Francisco J. Molina-Ruiz
Targeting the Regulatory Machinery of BIM for Cancer Therapy
Critical Reviews™ in Eukaryotic Gene Expression, Vol.22, 2012, issue 2
Steven Grant, Hisashi Harada
Yin Yang 1 in Human Cancer
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 3-4
Richard Byers, Khimara Naidoo, Sarah Nicholson, Helen Whitehouse
The Ideological Frame of the Genetic Basis of Cancer: The Important Role of miRNAs
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 3-4
Vassilis Zoumpourlis, Ioannis Christodoulou, Eleni Skourti, Maria Goulielmaki, Spiros Vlahopoulos